1. Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients With Lung Cancer 
Thibaut Lizée, MD, Ethan Basch, MD, MSc, Pierre Trémolières, MD, Eric Voog, MD, Julien Domont, MD, Guillaume Peyraga, MD, Thierry Urban, MD, Prof, Jaafar Bennouna, MD, Prof, Anne-Lise Septans, PhD, Magali Balavoine, MSc, Bruno Detournay, MD, Msc, Fabrice Denis, MD, PhD 
Journal of Thoracic Oncology 
Volume 14, Issue 6, Pages (June 2019)
DOI: /j.jtho
Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
Tornado diagram of the one-way sensitivity analysis representing the impact of each parameter variation on the incremental cost-effectiveness ratio (ICER). The parameters in order of their impact on the incremental cost-effectiveness ratio of the electronic patient-reported outcomes (e-PRO) surveillance strategy compared to the conventional follow-up. The parameters are arrayed along the vertical line, which represents the base case incremental cost-effectiveness ratio of €20,912 per quality-adjusted life year (QALY). Bars are arranged in the ascending order of their bar width. This width, which representing the degree of uncertainty, corresponds to the ICER variations for a value range (low and high value) of each parameter.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Scatter plot of the results of the multivariate probabilistic sensitivity analysis. The incremental cost-effectiveness ratio of each simulation is calculated as a ratio of incremental cost over incremental effectiveness in quality-adjusted life year (€/QALY). The results are filtered at 1000 dots of 10,000 simulations for the figure clarity. The circular line indicates the 95% confidence interval of incremental cost-effectiveness ratios (ICERs) among simulations. The dotted diagonal lines indicate the willingness-to-pay (WTP) thresholds with a slope of €30,000/QALY and €90,000/QALY. Dots below the lines are in favor of the very cost-effectiveness and cost-effectiveness, respectively, of the electronic patient-reported outcomes monitoring strategy.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

4. Figure 3
Cost-effectiveness acceptability curve. The results of the 10,000 simulations of the probabilistic sensitivity analysis are plotted on a cost-effectiveness acceptability curve showing the proportion of cost-effective simulations (y-axis) at different willingness-to-pay (WTP) thresholds (x-axis). This curve provides a probability that the electronic patient-reported outcomes monitoring strategy is cost-effective for a WTP threshold that a decision maker may consider acceptable. The probabilities that the experimental strategy is very cost-effective (WTP of €30,000/QALY) and cost-effective (WTP of €90,000/QALY) were 97% and 100%, respectively. QALY, quality-adjusted life year.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions